FiercePharmaOriginal article
{"a":[{"_":"Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags","$":{"href":"/pharma/neurocrines-blockbuster-hopeful-vykat-xr-tied-possible-safety-risks-prader-willi-clinicians","hreflang":"en"}}]}
RegulatoryVykat XRNegative
AI Analysis
Summary
Clinicians specializing in Prader-Willi syndrome have raised potential safety concerns about Neurocrine's approved drug Vykat XR, which was acquired through the company's $2.9 billion purchase of Soleno Therapeutics approximately 18 months ago.
Outcome Details
Safety concerns raised by clinicians regarding approved product
Importance:6/10
Sentiment:
-0.60
safety concernspost-marketacquisitionrare diseasePrader-Willi syndrome
Related Companies
Read the original article
Published by FiercePharma on August 12, 2026 6:05 PM
